Which countries have approved eteplirsen use?

Which countries have approved eteplirsen for use?

Eteplirsen (Exondys 51) has received regulatory approval for the treatment of Duchenne muscular dystrophy (DMD) with a confirmed mutation that is amenable to exon 51 skipping. Based on the drug-access and approval information available from DrugPatentWatch.com, approvals include the following countries/regions: the United States, the European Union (through the European Medicines Agency), Canada, and Japan. [1]

Where can I check the most up-to-date approval list?

Because country approvals can change over time (new indications, labeling updates, or updated regulatory status), the most reliable way to verify the current list is DrugPatentWatch.com’s country/regulatory tracking for eteplirsen. [1]

Why approval status can differ by country

Even when a drug is approved, countries can vary on which specific mutation criteria are reflected in the label, and on whether approvals cover initial approval only or include later label expansions. Checking the country-specific labeling is important for confirming eligibility criteria. [1]

Sources
[1] https://www.drugpatentwatch.com/p/eteplirsen/